Occurx
OccuRx is a biopharmaceutical company focused on innovative therapeutic strategies for ocular diseases associated with inflammation and fibrosis.Occurx
OccuRx Pty Ltd is a start-up company from the University of Melbourne that is developing new drugs that treat the cause of blindness that occurs in some diabetics. Diabetic eye disease includes the development of diabetic retinopathy, cataract (clouding of the lens) and glaucoma (increase ocular fluid pressure leading to optic nerve damage), which can cause severe vision loss and blindness. Diabetic retinopathy is the leading cause of new blindness in persons aged 25-74 in the United States and approximately 700,000 persons in the US have proliferative diabetic retinopathy, with an annual incidence of 65,000. Current treatments cannot restore lost vision and there is a need for new treatments that can control the disease. OccuRx’s lead compounds have been shown to be effective in animal models of fibrosis and diabetic eye disease and the company is progressing its lead drug into phase 1 clinical trials.
Blog Posts
5th June, 2023
OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in Boston
Melbourne, Australia, 05 June 2023: OccuRx, a biotechnology company focused on improving lives by de...
9th March, 2023
Celebrate World Kidney Day and Show your Kidneys some love.
Melbourne, Australia, 9 March 2023: OccuRx, a biotechnology company focused on improving lives by de...
9th January, 2023
OccuRx joins 41st Annual J.P. Morgan Healthcare Conference, San Francisco
Melbourne, Australia, 09 January 2023: OccuRx, a biotechnology company focused on improving lives by...
13th November, 2022
OccuRx raises awareness of the importance of World Diabetes Day
Melbourne, Australia, 14 November 2022: OccuRx, a biotechnology company focused on improving lives b...
17th October, 2022
OccuRx team to meet with biotech industry leaders during BIO-Europe® conference in Germany
Melbourne, Australia, 17 October 2022: OccuRx,a biotechnology company focused on improving lives by ...
13th October, 2022
OccuRx draws attention to World Sight Day to focus attention on the importance of eyecare
Melbourne, Australia, 13th October 2022: OccuRx, a biotechnology company focused on improving lives ...
9th September, 2022
$16M cash injection to progress first-in-class therapy for inflammation and fibrosis – Start Up Daily
Melbourne, Australia, 09 September 2022 written by Simon Thomsen: Australian biotech start-up OccuRx...
20th July, 2022
OccuRx secures $1.5M to advance its Phase II Chronic Kidney Disease Study
Melbourne, Australia, 20 July 2022: OccuRx has been awarded a $1.5m grant from CUREator, Australia’s...
20th June, 2022
OccuRx appoints Dr Gareth Lewis as Chief Commercial Officer
Melbourne, Australia, 20 June 2022: OccuRx, a biotechnology company focused on improving lives by de...
16th June, 2022
OccuRx represented at Biotechnology Innovation Organisation (BIO) International Convention in San Diego
Melbourne, Australia, 16 June 2022: OccuRx, a biotechnology company focused on improving lives by de...